Clinical trial • Phase I • Infectious Disease
CTX-187 for Bacterial infection
Phase I trial of CTX-187 for Bacterial infection. 68 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- Bacterial infection
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 23-03-2026
- First CTIS Authorization Date
- 30-04-2026
Trial design
Phase I trial across 1 site in Netherlands.
- Single Multiple Or Escalation Dose Combined
- Yes
- Target Sample Size
- 68
Recruitment
- Planned Sample Size
- 68
- Recruitment Window Months
- 8
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 68
Netherlands
- Earliest CTIS Part Ii Submission Date
- 27-04-2026
- Latest Decision Or Authorization Date
- 30-04-2026
- Processing Time Days
- 3
- Number Of Sites
- 1
- Number Of Participants
- 68
Sites
- Site Name
- Pharmaceutical Research Associates Group B.V.
- Department Name
- Program Management
- Contact Person Name
- Salah Hadi
- Contact Person Email
- Salah.Hadi@iconplc.com
Sponsor
Primary sponsor
- Full Name
- Centauri Therapeutics Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Investigational products
- Investigational Product Name
- CTX-187
- Routes Of Administration
- intravenous
- Route
- intravenous
Related trials
Other published trials that may interest you.
- Ciprofloxacin hydrochloride (ciprofloxacin) for Bacterial infection
- Conditioned medium from a co-culture of M2-macrophages and fat-derived mesenchymal cells for Acute respiratory distress syndrome (ARDS) | SARS-CoV-2 infection | Influenza A infection | Influenza B infection | Respiratory syncytial virus (RSV) infection
- ACICLOVIR for Recurrent herpes labialis | Herpes simplex labialis
- AMIKACIN SULFATE for Sepsis | Neutropenia
- LENACAPAVIR, ISLATRAVIR for HIV-1 infection